JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205

Volume 15 Issue 12, December 2025

Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

BIOTRANSFORMATION: THE IMPACT OF THE LIVER ON DRUG METABOLISM

Tashkent State Dental Institute / Tashkent

State Medical University Faculty of Pharmacy, 4th Year, Group 402

Students: ***Qayumova Dinara, Salohiddinova Sevinch***

Scientific Supervisor: ***N.A. Abzalova***

Annotation: This article examines the biochemical, physiological, and clinical aspects of hepatic biotransformation and its fundamental role in drug metabolism. It analyzes the structural and functional organization of hepatocytes, mechanisms of Phase I and Phase II metabolic reactions, the influence of enzymatic variability, genetic factors, pathological conditions, and drug–drug interactions on hepatic metabolism. The article also explores the significance of the cytochrome P450 system, conjugation pathways, plasma protein binding, and hepatic transporters. Moreover, the paper discusses the clinical implications of impaired liver function, dose adjustment strategies, and modern approaches to predicting metabolic pathways through pharmacokinetic modeling. Special attention is given to the integration of biotransformation studies in personalized medicine and drug development. The analysis demonstrates that the liver remains the central organ responsible for chemical transformation of xenobiotics, thereby determining the efficacy, safety, and pharmacokinetic profile of therapeutic agents.

Keywords: biotransformation, liver metabolism, cytochrome P450, drug metabolism, hepatocytes, Phase I reactions, Phase II reactions, xenobiotics, pharmacokinetics, hepatic clearance

Biotransformation represents a core physiological process by which the human body converts lipophilic substances into more hydrophilic derivatives that can be safely excreted. The liver, being the largest internal organ and an essential biochemical hub, performs the vast majority of these metabolic transformations. Its unique microarchitecture, abundant enzymatic machinery, and highly specialized cellular components make it the principal site where drugs undergo structural modification before elimination.Understanding hepatic biotransformation is critical in pharmacology because the metabolic fate of a drug determines not only its therapeutic potential but also its toxicity, half-life, bioavailability, and interaction with other agents. Many widely used medications—antidepressants, anticoagulants, anesthetics, antiepileptics, and analgesics—are primarily metabolized by hepatic enzymes. Variability in liver function, enzyme expression, genetic polymorphisms, and concurrent diseases can profoundly alter drug responses between individuals.

This article provides an in-depth overview of the mechanisms and clinical relevance of hepatic biotransformation, emphasizing how the liver shapes drug pharmacokinetics and overall therapeutic outcomes.The liver's role in biotransformation is closely tied to its anatomical and cellular organization. Hepatocytes constitute approximately 80% of liver mass and contain the highest concentration of drug-metabolizing enzymes in the human body. Their polarity, complex

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 12, December 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

membrane structures, and extensive smooth endoplasmic reticulum allow efficient uptake, transformation, and secretion of xenobiotics.

Blood supply also plays a critical role. The liver receives dual blood flow: nutrient-rich blood from the portal vein and oxygenated blood from the hepatic artery. This arrangement ensures that absorbed drugs reach hepatocytes almost immediately after intestinal absorption—a phenomenon known as the "first-pass effect." While this process protects the body from potentially harmful substances, it can significantly reduce the bioavailability of certain orally administered drugs such as propranolol, morphine, and nitrates.Kupffer cells, hepatic stellate cells, and sinusoidal endothelial cells support the overall metabolic process by participating in immune function, the synthesis of cofactors required for metabolism, and maintenance of the hepatic microenvironment.

Hepatic biotransformation is traditionally divided into Phase I and Phase II reactions, though some drugs undergo only one of these phases while others require both.Reductive reactions occur in low-oxygen environments and involve the addition of electrons to the drug molecule. They are mediated by reductases and enzymes associated with the endoplasmic reticulum. Drugs containing azo, nitro, or carbonyl groups are particularly susceptible to reductive metabolism.

Hydrolytic cleavage of ester and amide bonds occurs through esterases and amidases. This pathway is especially important for prodrugs, where hydrolysis activates the therapeutic form.

Phase II metabolism involves coupling the drug or its Phase I metabolite with endogenous hydrophilic molecules to facilitate excretion.One of the most prevalent conjugation reactions, glucuronidation, is mediated by UDP-glucuronosyltransferases (UGTs). Drugs such as morphine, lamotrigine, and bilirubin undergo glucuronidation. UGT polymorphisms influence toxicity and therapeutic efficacy.

Sulfotransferases add sulfate groups to phenols, alcohols, and amines. This pathway often competes with glucuronidation depending on substrate concentration.

N-acetyltransferases (NAT1 and NAT2) catalyze acetylation. Slow acetylators are at increased risk of toxicity from drugs like isoniazid and hydralazine

Methylation modifies catecholamines and neurotransmitters, while glutathione S-transferases detoxify reactive intermediates, preventing oxidative damage.

Genetic variation in CYP450, UGT, NAT, and GST enzymes profoundly affects drug metabolism rates. For example:CYP2D6 poor metabolizers exhibit reduced response to codeine because they cannot convert it to morphine.CYP2C9 variants alter warfarin metabolism, requiring personalized dose adjustments.These differences are central to personalized medicine and pharmacogenomics.

Neonates have immature metabolic pathways—especially glucuronidation—making them vulnerable to toxic accumulation. Conversely, elderly individuals often exhibit reduced hepatic

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 12, December 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

blood flow and enzyme activity.

Conditions such as cirrhosis, hepatitis, steatosis, and cholestasis impair hepatocyte function, reduce enzyme levels, and decrease drug clearance. Dose reduction is often necessary.

The CYP450 system comprises a superfamily of hemoproteins with remarkable substrate diversity. Their activity depends on cofactors, membrane environment, and genetic regulationCYP3A4 is the most abundant hepatic isoform, metabolizing anesthetics, antihistamines, benzodiazepines, calcium channel blockers, and many more. CYP2D6, though less abundant, handles critical cardiovascular and neuropsychiatric drugs.

CYP1A2 primarily metabolizes caffeine and certain antipsychotics, while CYP2C9 and CYP2C19 metabolize NSAIDs, anticonvulsants, and proton pump inhibitors. Variability in the expression of these enzymes influences drug efficacy across global populationsDrugs taken orally undergo significant hepatic metabolism before reaching systemic circulation. Understanding the extent of first-pass metabolism helps determine dose, route of administration, and formulation.Some drugs generate hepatotoxic intermediates. Acetaminophen metabolism produces N-acetyl-p-benzoquinone imine (NAPQI), which can cause liver failure when glutathione reserves are depleted.

Biotransformation pathways become saturated during overdose, leading to accumulation of toxic compounds.

Patients with liver dysfunction require tailored dosing regimens. Drugs with high hepatic extraction ratios—such as propranolol or lidocaine—show drastically altered pharmacokinetics in hepatic disease. Advances in pharmacokinetic modeling, in vitro cell culture systems, mass spectrometry, and genomic analysis allow researchers to predict metabolic pathways more accurately. Hepatocyte cultures, liver microsomes, and recombinant enzyme systems are widely used to identify metabolic profiles during drug development.

Machine-learning models increasingly help predict metabolism based on chemical structure, enhancing safety assessment and optimization of new drugs. As pharmacogenomics advances, biotransformation becomes a central pillar of individualized therapy. Genetic screening enables prediction of metabolic capacity, informing dose selection and drug choice. Personalized strategies reduce adverse reactions, enhance efficacy, and improve patient outcomes.

The liver plays an indispensable role in drug metabolism through its highly specialized enzymatic and cellular systems. Biotransformation determines the pharmacokinetic behavior, therapeutic success, and safety of medications. Understanding the complexity of hepatic metabolism—its phases, enzymes, variability factors, and pathological implications—is essential for rational drug therapy and effective clinical decision-making. With continued advances in molecular biology and pharmacogenomics, the study of biotransformation will remain a cornerstone of personalized medicine, guiding the development of safer and more effective therapeutic agents.

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205

Volume 15 Issue 12, December 2025

Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

References

1. Parkinson, A., & Ogilvie, B.W. Biotransformation of Xenobiotics. In: Klaassen C.D. (Ed.) Casarett & Doull's Toxicology. 8th ed. McGraw-Hill; 2013: 185–366.

2. Guengerich, F.P. Cytochrome P450 and Chemical Toxicology. Chemical Research in Toxicology. 2008;21(1):70–83.

3. Zanger, U.M., & Schwab, M. Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacology & Therapeutics. 2013;138(1):103–141.

4. Wilkinson, G.R. Drug Metabolism and Variability Among Patients in Drug Response. New England Journal of Medicine. 2005;352:2211–2221.

5. Court, M.H. Interindividual Variability in Hepatic Drug Glucuronidation: Studies into the Role of Age, Genetic Polymorphisms, and Environmental Factors. Drug Metabolism Reviews. 2010;42(1):209–224.

6. Rendic, S., & Guengerich, F.P. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in Drug Metabolism. Chemico-Biological Interactions. 2015;234:199–221.

7. Waxman, D.J., & Holloway, M.G. Sex Differences in Hepatic Drug Metabolism: Regulation of Cytochrome P450 by Growth Hormone. Journal of Clinical Investigation. 2009;126(2):467–475.

8. Wrighton, S.A., & Stevens, J.C. The Human Hepatic Cytochromes P450 Involved in Drug Metabolism. Critical Reviews in Toxicology. 2015;25(1):1–18.

9. Nelson, D.R. The Cytochrome P450 Gene Superfamily. Human Genomics. 2018;13(1):18.

10. European Medicines Agency (EMA). Guideline on the Investigation of Drug Interactions. 2012; 10–30.